UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies, today announced the appointment of Greg Perry as the Company’s Chief Financial Officer (CFO). Additionally, Greg has been designated as the Company’s principal financial officer, succeeding Bill Lundberg, M.D., in such role. In connection with his appointment as the Company’s Chief Financial Officer, on June 14, 2023, Greg resigned from the Company’s Board of Directors.
“I am excited to welcome Greg as our CFO and look forward to drawing from his broad biotech experience in capital finance and strategic transactions, and deep knowledge of our business,” said Bill Lundberg, M.D., President, Chief Executive Officer of Merus. “Greg brings industry-leading financial acumen and has been a great source of insight on the Merus Board of Directors. I’m looking forward to working with him full time as we continue to advance the Company through the exciting opportunities that lie ahead.”
Greg Perry has served as a non-executive director of the Merus Board of Directors since May 2016 and Vice Chair of the Board since August 2018. Greg remains a non-executive director of the Board of Directors of Kala Pharmaceuticals, a role he has held since March 2018. Prior to joining Merus, Greg was the CFO of Finch Therapeutics from May 2018 through April 2022. Previously Greg held various senior financial leadership roles at several biotech companies including Novelion Therapeutics, Eleven Biotherapeutics, ImmunoGen, Domantis, and Transkaryotic Therapies. Greg transitioned to the biotech industry after beginning his career at General Electric, where he served in increasingly senior financial roles over fourteen years. He earned a B.A. in Economics and Political Science from Amherst College.
“I am delighted to join the team at Merus, during this compelling next chapter for the Company, following the truly remarkable petosemtamab interim clinical data presented this Spring at AACR, as we move to a later-stage clinical development company, with a terrific pipeline and compelling platform,” said Greg Perry, CFO, Merus.
About Merus N.V.
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and Twitter.
